Le Lézard
Classified in: Health, Science and technology
Subject: Personnel

Former Merck Director and Vanderbilt Vice-Chancellor, Dr. Harry Jacobson, to Join Lobe Sciences Board of Directors


Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced that Dr. Harry Jacobson has agreed to join its Board of Directors in the coming months.

Dr. Jacobson brings over three decades of distinguished experience in healthcare, biotechnology, and medical innovation. As a serial entrepreneur, executive and visionary leader, his extensive knowledge and strategic insights will be invaluable to Lobe Sciences as the company continues to pioneer groundbreaking treatments and expand its footprint in the development of transformative medicines for orphan and rare diseases.

"We are thrilled to welcome Dr. Jacobson to our Board of Directors," said Philip J. Young, Chairman and CEO of Lobe Sciences. "Dr. Jacobson's remarkable track record in healthcare and his passion for advancing medical science align perfectly with our mission to transform the development of treatments for neurologic diseases. His expertise will be instrumental as we navigate the evolving landscape to develop and commercialize our lead programs for Chronic Cluster Headaches and Sickle Cell Disease."

Board certified in Internal Medicine and Nephrology, Dr. Jacobson joined Vanderbilt Medical Faculty in 1985 as Professor of Medicine and Director of the Division of Nephrology. After developing one of the nation's premier nephrology divisions, Dr. Jacobson was named Vice Chancellor for Health Affairs and CEO of the Vanderbilt University Medical Center (VUMC).

As Vice Chancellor for Health Affairs, Dr. Jacobson's 12-year tenure saw the VUMC budget expand from $750M to $2.5B, all the while delivering superior care. Vanderbilt's federally funded research moved from 24th to top 10 in the country and more than $1B of newly constructed facilities were opened. Among these projects are the Monroe Carell Children's Hospital and Vanderbilt Health at 100 Oaks.

During the course of his career, Dr. Jacobson has been a successful investor and entrepreneur, having founded or co-founded several companies, including Contact Software, the developer of the software program ACT which helped launch the CRM software category; Renal Care Group; Cardiovascular Care Group; Informatics Corporation of America; CeloNova Biosciences, Ambulatory Services of America; MindCare Solutions; Innovative Renal Care; MedLogic, and For Better Health (4BH). He has served on the boards of three New York Stock Exchange companies including Merck, Kinetic Concepts, and Renal Care Group. Currently, Dr. Jacobson serves on the Board of Directors of several healthcare companies from the original MedCare portfolio. In 2013, Dr. Jacobson served Belmont's Jack C. Massey Graduate School of Business as its Distinguished Healthcare Executive-in-Residence and was Chairman of the McWhorter Society from 2014 to 2017.

"I am excited to join Lobe Sciences at such a pivotal time in the company's growth," said Dr. Jacobson. "The potential of their neurologic and Sickle Cell Programs to change the lives of patients around the globe is inspiring and I look forward to working with the talented team at Lobe Sciences to advance their promising pipeline of therapies."

About Lobe Sciences Ltd.

Lobe Sciences is a biopharmaceutical company focused on developing transformative medicines to treat rare diseases. The Company, through collaborations with industry-leading partners, is additionally engaged in drug research and development using non-hallucinatory doses of stabilized psilocin based compounds to address unmet medical needs in orphan neurological therapeutic applications.

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

This does not constitute an offer to sell or a solicitation of offers to buy any securities.

Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this news release (including, without limitation, statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness) are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; that the Company's drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company's corporate goals and objectives; and other risk factors detailed in the Company's continuous disclosure filings from time to time, as available under the Company's profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.


These press releases may also interest you

at 12:45
SummaryProducts: Dianeal PD4 2.5% Dextrose peritoneal dialysis solution (3,000 mL and 5,000 mL); Physioneal 40 2.27% Glucose peritoneal dialysis solution (2,500 mL)Issue: Health products ? Product safetyWhat to do: Immediately check your stock to see...

at 10:45
Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") and certain officers. The class action, filed in the United States District Court for the District of Maryland, Southern...

at 10:30
IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, presented clinical data on the use of Equecabtagene Autoleucel (Eque-cel),...

at 10:05
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today statistically significant and clinically meaningful results from its Phase III STARGLO study of Columvi® (glofitamab-gxbm) in combination with gemcitabine and...

at 09:00
The Minister of Labour and Seniors, Seamus O'Regan Jr., and the Minister of Mental Health and Addictions and Associate Minister of Health, Ya'ara Saks, issued the following statement on World Elder Abuse Awareness Day: "Elder abuse is a crime that...

at 09:00
From June 15 to July 15, the premium health supplement brand, Vimergy, will be featured in the Medical Medium created smoothie, available at all Erewhon locations. Created by Medical Medium Anthony William, the smoothie will feature Vimergy Barley...



News published on and distributed by: